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Introduction
The protein Cluster of Differentiation 74 (CD74)
is a type II transmembrane molecule that acts as a
receptor for macrophage migration inhibitory
factor (MIF) when it displays on the cell surface.
The interaction between MIF and CD74 initiates
oncogenic signaling in cancer to control the growth
of a tumor. Our previous study showed this
interaction was relevant in advanced melanoma1
(Fig. 1). CD74 alone does not function to signal
these pathways but does so with help of others
including CD44, a non-kinase transmembrane
glycoprotein, acting as a transducing co-receptor.
Although it has been demonstrated that CD74 has
four different isoforms (p31, p33, p41, and p43)2, it
is unclear which isoform makes this complex with
CD44 to initiate the oncogenic signaling pathways
in melanoma.
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Objectives
Our group has previously shown that autocrine
MIF-CD74 interactions in response to interferon-γ
(IFN-γ) induced oncogenic pAKT pathway and
tumor progression in cutaneous melanoma3.
However, we have not shown whether the
interaction between MIF and CD74/CD44 binding
induces the oncogenic signaling.
In this proposal, we aim to identify
(1) if the binding of MIF/CD74/CD44 signaling is
involved in oncogenic pAKT pathways
(2) which CD74 isoform makes the complex with
CD44
in melanoma.

Fig. 2 Induction of CD74 by IFN-γ stimulation.
(A) qRT-PCR data showed that IFN-γ (20, 100, and 500 IU/mL)
dramatically increased the mRNA CD74 expression in A375 and
SB2. (B) WB analysis of change in CD44 and CD74 expression after
IFN-γ stimulation (20, 100, and 500 IU/mL) in A375 and SB2. Actin
was used as a loading control. (C) Flow cytometry analysis showed
that IFN-γ stimulation (20, 100, and 500 IU/mL) increased the cell
surface CD74expression in A375 and SB2.

Fig. 3. Activation of AKT signaling after rhMIF stimulation.
We compared the p-AKT expression 0, 10, 30, and 120 min after 100
ng/mL rhMIF exposure under basal and IFN-γ stimulatory conditions
in A375 and SB2. Total AKT was used as a loading control.
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Fig. 1: Representative image of multiplex immunohistochemistry for
CD74 (green), CD44 (red), and MIF (yellow) in patients with stage IV
Melanoma. Unpublished.

Methods
Cell lines:
A375 (BRAF-mutant melanoma cell line),
SB2 (NRAS-mutant melanoma cell line)
Experimental overview
(1) Induction of the cell surface CD74 by
recombinant human (rh) IFN-γ stimulation.
[Methods] We stimulated A375 and SB2 with
different concentration of rhIFN-γ (0, 20, 100, and
500 IU/mL) and evaluated the CD74 expression by
real-time quantitative reverse transcription
polymerase chain reaction (qRT-PCR), western
blotting (WB), and flow cytometry.
(2) Activation of the AKT pathway by the
binding of MIF to cell-surface CD74,
induced by IFN-γ.
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Fig. 4. Activation of AKT signaling after rhMIF stimulation after
knocking down of CD74 and CD44
(A, B) Efficacies of two individual siRNAs in knocking down CD74
(A) and CD44 expression (B) were analyzed by WB in A375 and
SB2 under 100 IU/mL IFN-γ stimulated conditions. SC siRNA was
used as a control. (C) Under 100 IU/mL IFN-γ stimulated conditions,
we compared the p-AKT expression 0, 10, and 30 min after 100
ng/mL rhMIF stimulation in A375 and SB2, transfected with
scramble (SC) siRNA, CD74 si-2, CD44 si-2 and double (CD74 si-2
and CD44 si-2) by WB. Total AKT was used as a loading control.

[Methods] We pre-treated A375 and SB2 with
100 IU/mL rhIFN-γ (no IFN-γ stimulation for
control) for 24 h to induce the cell-surface
CD74 expression and sequentially stimulated
by 100 ng/mL rhMIF. After 0, 10, 30, and 120
min exposures to rhMIF, we prepared the cell
lysates to evaluate p-AKT expression by WB.
(3) Interaction between MIF and
CD74/CD44 binding is involved in the
AKT pathway.
[Methods] The change in p-AKT expression 0,
10, and 30 min after 100 ng/mL rhMIF
exposure was evaluated by WB with knocking
down of CD74 and CD44 (as single and
double) by short interfering (si)RNA in A375
and SB2. Scramble (SC) siRNA was used as a
control.
(4) Identification of the isoform of CD74 that
complexes with CD44
[Methods] We will pre-treat A375 and SB2 with
100 IU/mL rhIFN-γ for 24 h to induce cellsurface CD74 expression and perform
CD44/CD74 co-immunoprecipitation, followed
by WB.

Results

(1) Induction of the cell surface CD74 by
IFN-γ stimulation.
CD74 mRNA expression was dramatically
upregulated in response to IFN-γ in A375 and
SB2 by q-RT PCR (Fig. 2A). The upregulation
of 3 isoforms of CD74 (p33, p35, and p41)
under IFN-γ stimulatory conditions were
found in A375 and SB2 by WB (Fig. 2B). On
the contrary, the CD44 expression was not
affected by IFN-γ (Fig. 2B). In addition, flow
cytometry analysis revealed that the cellsurface CD74 was induced by IFN-γ,
particularly in SB2 (Fig. 2C).
(2) Activation of the AKT pathway by the
binding of MIF to cell-surface CD74,
induced by IFN-γ.
In order to explore if binding of MIF to cellsurface CD74 initiates AKT signaling, we
compared the p-AKT expression 0, 10, 30, and
120 min after rhMIF exposure under basal and
IFN-γ stimulatory conditions. As shown in
Fig. 3, the upregulation of p-AKT expression
after rhMIF stimulation was more marked in
A375 and SB2 pre-treated with rhIFN-γ than
in those cultured in basal conditions,
particularly clearer in SB2. These results
indicate the interaction between MIF and the
cell-surface CD74, induced by IFN-γ,
activates oncogenic signaling pathway in
melanoma.
(3) Interaction between MIF and
CD74/CD44 binding is involved in the
AKT pathway.

Results (continued)
In order to assess if MIF/CD74/CD44
signaling is involved in the activation of the
AKT pathway, we silenced CD74 and/or
CD44 by siRNA. We prepared siRNA reagents
targeting 2 different sequences of CD74 and
CD44 (si-1 and si-2, respectively). Efficacies
of transfection were confirmed by WB (Fig.
4A, B) and CD74 si-2 and CD44 si-2 were
used for the following experiment. Next,
under 100 IU/mL rhIFN-γ stimulated
conditions, we compared the p-AKT
expression 0, 10, and 30 min after 100 ng/mL
rhMIF stimulation in A375 and SB2 between
cells transfected by scramble (SC) siRNA,
CD74 si-2, CD44 si-2 (single), and CD74 si2/CD44 si-2 (double). When compared, cells
with SC siRNA, p-AKT expression was
slightly decreased in cells with CD74 si-2 and
was remarkably attenuated in cells with CD44
si-2 (Fig. 4C). Furthermore, AKT signaling
was synergistically suppressed in SB2 with
double knocking down of CD74 and CD44.
(4) Identification of the isoform of CD74 that
complexes with CD44
Lastly, in order to identify the isoform of
CD74 that complex with CD44, we will
collect cell lysates after 100 IU/mL rhIFN-γ
stimulation and perform CD44/CD74 coimmunoprecipitation, followed by WB.

Conclusions
The present study showed that the three isoforms
of CD74 (p33, p35, and p41) was upregulated by
IFN-γ, and the interaction between MIF and
CD74/CD44 was associated with the activation of
the AKT signaling pathway in melanoma.
We are currently studying to identify the isoforms
of CD74 (p33, p35, and p41) that complexes with
CD44. Given that CD74 also works as a chaperon
for MHC-class II, it may be unpreferable to inhibit
the functions of all isoforms of CD74.
In this regard, our result may not only provide a
better understanding of the signaling pathways, but
also help develop the therapeutic drug
against the specific isoform of CD74 that is
associated with the promotion of oncogenic
signaling in melanoma.
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